Antidepressants Drugs Market to Grow at CAGR of 7.90% through 2032 – Favourable Government Initiatives to Reduce Ecological Footprints & Decarbonization

The developing attention to psychological wellness issues and efforts to decrease the stigma related to looking for treatment are huge drivers for the antidepressant drugs market. A positive change in mentalities frequently relates to higher solution rates for antidepressant drugs, adding to the development of the antidepressant market.

Newark, Jan. 29, 2024 (GLOBE NEWSWIRE) — As per the report published by The Brainy Insights, the global antidepressants drugs market is expected to grow from USD 17.02 billion in 2022 to USD 36.41 billion by 2032, at a CAGR of 7.90% during the forecast period 2023-2032.

Download Free Sample Report (Get Detailed Analysis in PDF – 230 Pages): https://www.thebrainyinsights.com/enquiry/sample-request/13994

Depressive disorders, mood disorders, and other conditions marked by persistent sadness, low mood, or lack of interest in activities are treated with antidepressant medications. These medications influence the degrees of neurotransmitters, which are chemical substances that communicate signals in the brain. Serotonin, norepinephrine, and dopamine are the neurotransmitters that are most frequently targeted by antidepressant medications. Antidepressant drugs offer a few advantages in the treatment of state of mind problems, especially depression and certain anxiety disorders. The brain’s modulation of neurotransmitters and other mechanisms are the means by which these advantages are achieved. Antidepressants are profoundly compelling in lessening the side effects of significant burdensome problems. Antidepressants can fundamentally decrease self-destructive considerations and ways of behaving related to serious sorrow. By successfully treating sadness, antidepressants add to limiting the cultural and financial weight related to untreated or under-treated psychological well-being conditions. Reaction to antidepressants fluctuates among people, and the decision of prescription might be customized in light of elements like side effects, medical history, and genetic considerations. Antidepressant drugs are used among youngsters because of multiple factors, basically to address psychological wellness conditions that might influence their profound prosperity and day-to-day work. The choice to endorse antidepressants to youths is normally made in light of a cautious assessment of the seriousness of side effects, the effect on day-to-day existence, and the potential advantages versus risks. Depression is a critical emotional wellness worry among youngsters, and antidepressants are endorsed to ease burdensome side effects. Youngsters may experience panic attacks, and antidepressants can be prescribed to manage panic symptoms. Antidepressants can be effective in reducing suicidal thoughts and behaviors among young individuals.

Report Scope & Segmentation

Report Attribute	Details
Revenue forecast in 2032	USD 36.41 Billion
Growth Rate	7.90%
Base Year	2022
Historic Years	2019 – 2021
Forecast Years	2023 – 2032
Segments Covered	Drug Class, Indication, Route of Administration, End-User
Regions Covered	North America,  Europe,  Asia Pacific,  South America,  and Middle East & Africa,  and Rest of World
Number of Companies Covered	Amneal Pharmaceutical Inc, Aurobindo Pharma, Avet Pharmaceuticals Inc., Currax Pharmaceuticals LLC, Endo Pharmaceuticals plc, GlaxoSmithKline plc., Johnson & Johnson, Mallinckrodt, Mayne Pharma Group Limited, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, Viatris, WOCKHARDT, Zydus Cadila
Report Coverage	Product offering, business overviews, geographic presence,  business strategies,  segment market share,  product development & amp; innovations,  recent developments,  joint venture,  partnerships,  mergers & acquisitions,  strategic alliances,  SWOT analysis,  and key financial information.

There is an expanded risk of suicidal thoughts and behaviors, especially in kids, youths, and young adults, during the initial phases of treatment. Antidepressants might connect with different medications, prompting possible harmful effects. Weight gain is a typical side effect of certain antidepressants. Antidepressants can cause disturbances in sleep patterns, leading to either insomnia or excessive sedation.
 
Market Growth & Trends

The demand for mental health treatments, including antidepressants, has increased as a result of rising awareness of mental health issues. Governments and healthcare organizations emphasize the importance of mental health, potentially driving investment in research and development of mental health medications. Continuous research explores novel therapeutic approaches, including developing new classes of antidepressants or medications with faster onset of action. Digital therapeutics, including versatile applications for emotional well-being and telemedicine stages, are being incorporated to upgrade treatment results and patient adherence. Drug organizations are shaping joint efforts and associations to share skills, assets, and exploration discoveries in improving emotional wellness prescriptions. The attention to further improving side effect profiles in antidepressant drugs can add to the development of the market in many ways. While the viability of medicine in treating discouragement remains an essential thought, addressing side effects is crucial for enhancing patient adherence, satisfaction, and overall treatment outcomes. Antidepressant medications with further improved aftereffect profiles are bound to be tolerated by patients, prompting lower paces of treatment discontinuation. Antidepressant patients benefit from a higher quality of life overall when side effects are minimized.

If you have any questions, please feel free to contact our analyst at: https://www.thebrainyinsights.com/report/antidepressants-drugs-market-13994

Key Findings

• In 2022, the selective serotonin reuptake inhibitors segment dominated the market with the largest market share of 20.25% and market revenue of USD 3.45 billion.

The drug class segment is divided into reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin antagonist and others. In 2022, the selective serotonin reuptake inhibitors segment dominated the market with the largest market share of 20.25% and market revenue of USD 3.45 billion.

• In 2022, the major depressive disorder segment accounted for the largest share of the market, with 35.58% and a market revenue of USD 6.06 billion.

The indication segment is divided into major depressive disorder, anxiety disorders, attention deficit hyperactivity disorder and others. In 2022, the major depressive disorder segment accounted for the largest share of the market, with 35.58% and a market revenue of USD 6.06 billion.
 
• In 2022, the oral segment dominated the market with the largest market share of 74.25% and market revenue of USD 12.64 billion.

The route of administration segment is divided into oral and injectable. In 2022, the oral segment dominated the market with the largest market share of 74.25% and market revenue of USD 12.64 billion.

• In 2022, the hospitals & speciality centers segment dominated the market with the largest market share of 69.35% and market revenue of USD 11.80 billion.

The end-user segment is divided into hospitals & speciality centres and homecare. In 2022, the hospitals & speciality centers segment dominated the market with the largest market share of 69.35% and market revenue of USD 11.80 billion.

• In 2022, the hospital pharmacy segment accounted for the largest share of the market, with 58.98% and a market revenue of USD 10.04 billion.

The sales channel segment is divided into hospital pharmacy, online pharmacy and retail pharmacy. In 2022, the hospital pharmacy segment accounted for the largest share of the market, with 58.98% and a market revenue of USD 10.04 billion.

Any query or customization before buying: https://www.thebrainyinsights.com/enquiry/request-customization/13994

Regional Segment Analysis of the Antidepressants Drugs Market

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America)
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Among all regions, the North America region emerged as the largest market for the global antidepressants drugs market, with a market share of around 38.98% and USD 6.63 billion of the market revenue in 2022. The North American region is expected to be the largest market forecast period. The increase in the pervasiveness of emotional well-being conditions, including discouragement and uneasiness, has been seen in North America. This pattern has added to a developing interest in antidepressant medications. There is a growing emphasis on personalized medicine in psychological wellness, expecting to tailor treatment approaches, including the choice of antidepressant medications, because of individual patient qualities, hereditary qualities, and reactions to treatment. Pharmaceutical companies keep putting resources into innovative work to find and showcase novel antidepressant drugs with improved efficacy, faster onset of action, and fewer side effects compared to existing medications.

Key players operating in the global antidepressants drugs market are:

• Amneal Pharmaceutical Inc
• Aurobindo Pharma
• Avet Pharmaceuticals Inc.
• Currax Pharmaceuticals LLC
• Endo Pharmaceuticals plc
• GlaxoSmithKline plc.
• Johnson & Johnson
• Mallinckrodt
• Mayne Pharma Group Limited
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd
• Viatris
• WOCKHARDT
• Zydus Cadila

This study forecasts global, regional, and country revenue from 2019 to 2032. The Brainy Insights has segmented the global antidepressants drugs market based on the below-mentioned segments:

Global Antidepressants Drugs Market by Drug Class:

• Reuptake inhibitors
• Serotonin-Norepinephrine Reuptake Inhibitors
• Monoamine Oxidase Inhibitors
• Tricyclic Antidepressants
• Selective Serotonin reuptake Inhibitors
• Serotonin Antagonist
• Others

Global Antidepressants Drugs Market by Indication:

• Major Depressive Disorder
• Anxiety Disorders
• Attention Deficit Hyperactivity Disorder
• Others

Global Antidepressants Drugs Market by Route of Administration:

• Oral
• Injectable

Global Antidepressants Drugs Market by End-Users:

• Hospitals & Speciality Centers
• Homecare

Global Antidepressants Drugs Market by Sales Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

About the report:

The global Antidepressants Drugs market is analyzed based on value (USD Billion). All the segments have been analyzed worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report analyzes driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, supply, and demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients’ objectives of high-quality output within a short span of time. We provide both customized (clients’ specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients’ requirements whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D
Head of Business Development
Phone: +1-315-215-1633
Email: [email protected] 
Web: http://www.thebrainyinsights.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.